Rise of the Purple Mold: How Purpureocillium lilacinum Is Quietly Creeping into Healthcare

It doesn’t come with a horror movie name. It doesn’t produce black slime on your bathroom ceiling. And it won’t trigger a CDC emergency alert—yet.
But Purpureocillium lilacinum, the delicate purple-hued mold once known only to soil scientists and greenhouse workers, is making a slow, strange climb into the clinical spotlight.

A recent nationwide surveillance study in the U.S. uncovered something unexpected: fungal cultures submitted to Labcorp between 2019 and 2025 showed a steady rise in P. lilacinum detections—from 56 to 74 per 100,000 cultures in just a few years, with some quarters spiking even higher.
That may seem minor—until you realize that most medical mycology trends don’t shift that fast without a reason.

What Is This Mold, and Why Should We Care?

P. lilacinum isn’t new. It’s been used for years in agriculture as a biopesticide, especially for controlling nematodes in crops. Organic farming? Greenhouses? Tree farms? This mold’s already there, doing its job.
But now it’s turning up in people’s sputum, eyes, skin lesions, even blood.

While it rarely causes disease in healthy individuals, it can become a serious problem for immunocompromised patients. And worse? It resists amphotericin B—a frontline antifungal drug. That means if you miss the ID, or confuse it with another species, you could be treating with the wrong tool for weeks.

And that matters when lives are on the line.

A Mold That Hitches Rides

The study found that P. lilacinum showed up most in samples from the South Atlantic and Pacific states—humid, warm, and agriculturally active zones. It favored respiratory specimens, pointing toward possible airborne transmission or environmental exposure. Men over 65 were the most common demographic for positive cultures.

But let’s be clear: not all detections equal infection. Some cases may reflect simple colonization or lab contamination. Still, if you see a pattern forming, the next question is: why now?

Agriculture Meets Hospital Corridor

Here’s the theory raised by researchers: as agricultural use of P. lilacinum increases, so too does environmental exposure. The spores don’t just stay on the farm.
They drift, they stick to boots, they ride on produce—and maybe even circulate through hospital ventilation.

For someone with a weakened immune system, a soil-friendly mold can turn unfriendly fast.
One pseudo-outbreak described in the study seemed to come not from patient-to-patient spread, but from the environment itself.
That blurs the line between clinical infection and ecological consequence.

Why This Quiet Rise Deserves Attention

Let’s not make the mistake of ignoring P. lilacinum just because it doesn’t scream like Candida auris or charge in like Aspergillus fumigatus.
This mold plays the long game.

• It grows slowly, so clinical labs may miss or underestimate it.
• It resists a major antifungal drug.
• It thrives in high-organic, moist environments—just like many hospitals, greenhouses, and homes.

More importantly, its rise could signal a broader ecological shift: a future where fungi used in agriculture begin creeping into medicine.
Where the solution to nematodes might someday become the problem in intensive care units.

What We Need to Do

1. Improve Lab Detection – Clinical labs should be trained to identify P. lilacinum and distinguish it from contaminants or commensals.
2. Monitor Agricultural Use – Regulatory bodies like EPA and FAO must assess where and how much P. lilacinum is applied, including human health impact.
3. Study Cross-Exposure Pathways – Research how spores travel from farms to clinics, and who’s most at risk.
4. Create Clear Reporting Guidelines – Not all positives are infections, but all deserve documentation. Current surveillance is patchy at best.

P. lilacinum may not be famous. It may not be deadly in every case. But it’s climbing the charts for a reason.
And if we want to stay ahead of fungal risks in a changing world—where climate, agriculture, and health are increasingly intertwined—we need to listen to the quiet ones, too.

Because sometimes, the most important molds are the ones that don’t make a scene—they make a shift.

Frequently Asked Questions

What is Purpureocillium lilacinum and where is it found?

Purpureocillium lilacinum (formerly classified as Paecilomyces lilacinus before molecular phylogenetic reclassification) is a filamentous fungus belonging to the order Hypocreales, family Ophiocordycipitaceae—the same family as Cordyceps (the famous insect-parasitising fungi). It is widely distributed in nature: found in soils on every continent; particularly common in tropical and subtropical soils; associated with decaying plant matter, insects, nematodes (roundworms), and occasionally with mammalian skin. Its characteristic feature is the production of pastel lilac to purple spore masses (conidia) on conidiophores—the pigmented masses are what give it its species name (lilacinum means ‘lilac-coloured’). Ecological role: P. lilacinum is an entomopathogenic and nematophagous fungus—it infects and kills nematodes and insects, using them as food sources; this ecological role has been harnessed commercially: P. lilacinum (sold as BioAct, MeloCon, and other trade names) is used as a biological control agent against plant-parasitic nematodes in agriculture across more than 50 countries; it is applied to soil to control nematode pests in vegetable, fruit, and ornamental plant production. Clinical significance: historically considered a rare, occasional laboratory contaminant or extremely rare human pathogen; its clinical significance has grown substantially over the past 20 years as immunocompromised patient populations have expanded and molecular laboratory identification has improved, allowing routine identification of species previously classified generically.

How does Purpureocillium lilacinum infect humans?

P. lilacinum infects humans through several distinct pathways depending on the clinical presentation and the patient’s immune status. Environmental inhalation: as a soil fungus releasing airborne conidia, P. lilacinum can be inhaled; in immunocompetent individuals, inhaled spores are efficiently cleared by alveolar macrophages and mucociliary clearance without causing disease; in severely immunocompromised patients (particularly those with prolonged neutropenia), inhaled spores may germinate and cause invasive pulmonary infection, analogous to invasive aspergillosis. Traumatic inoculation: direct implantation of the fungus through skin wounds, particularly injuries involving soil or plant material, can establish localised subcutaneous infection; these infections can occur in immunocompetent individuals if the inoculum is sufficiently large; cases of onychomycosis (nail infection) following nail injury have been reported. Ocular exposure via contact lenses: contaminated contact lens care solutions, lens cases, or contact lenses themselves can deliver P. lilacinum directly to the corneal surface; the compromised corneal epithelium under contact lenses and microscopic abrasions from lens wear create vulnerability; this is the best-documented route of infection in otherwise immunocompetent individuals. Medical procedure-related: infection of peritoneal dialysis catheters (causing fungal peritonitis), surgical wound infections, and eye infections following ophthalmic surgery have been reported; contaminated medical equipment or solutions may be the source in some cases.

How is Purpureocillium different from common black mold?

Purpureocillium lilacinum and Stachybotrys chartarum (‘black mold’) are completely unrelated fungi with different ecology, appearance, health implications, and clinical significance. Fundamental differences: taxonomic relationship—P. lilacinum belongs to the order Hypocreales; Stachybotrys belongs to the order Hypocreales but is in a completely different family (Stachybotryaceae); they share the same order but have vastly different biology and ecology. Appearance—P. lilacinum produces pastel lilac/purple spore masses; Stachybotrys produces jet-black, slimy spore masses; visually completely distinct when properly identified. Ecology—P. lilacinum is primarily a soil organism and is more commonly found outdoors and in agricultural settings; Stachybotrys requires very high moisture and is strongly associated with building materials with chronic water damage (drywall, wood, paper); S. chartarum is rare in soil environments. Toxin production—Stachybotrys is well-known for producing macrocyclic trichothecene mycotoxins including satratoxins; P. lilacinum does not produce significant mycotoxins; the health concerns are different in nature. Infectivity—P. lilacinum causes opportunistic infections, particularly in immunocompromised patients; Stachybotrys does not cause invasive infections even in immunocompromised patients and is primarily a concern through environmental mycotoxin exposure. Clinical prevalence—both are relatively uncommon in clinical practice; Stachybotrys is more commonly encountered as an environmental contaminant in water-damaged buildings, while P. lilacinum more commonly appears in clinical cultures from immunocompromised patients.

Can agricultural use of Purpureocillium as a biopesticide increase human exposure?

This is a legitimate and underexplored question in occupational health and environmental mycology. P. lilacinum is registered as a biopesticide for nematode control in numerous countries and is applied to agricultural soils at significant scale. Exposure pathways in agricultural settings: soil application creates increased local soil concentrations of P. lilacinum; soil disturbance during planting, cultivation, and harvest generates airborne dust containing fungal spores; agricultural workers performing these operations have the highest potential exposure. Current evidence: there are no large-scale occupational health studies specifically examining P. lilacinum infection rates in agricultural workers who use it as a biopesticide; regulatory risk assessments for biopesticide registration (performed by EPA in the US and EFSA in Europe) have classified P. lilacinum as not likely to cause infection in healthy individuals based on available evidence. Risk assessment considerations: the same properties that make P. lilacinum useful as a biopesticide (ability to infect nematodes and insects) also reflect its potential as an opportunistic pathogen; immunocompromised agricultural workers (immunosuppressive medications, HIV, chemotherapy recipients) may represent a population at elevated risk; occupational exposure during periods of high soil disturbance (ploughing, transplanting) could increase inhalation exposure. Regulatory agency position: EPA has classified P. lilacinum as a ‘Category 3’ biopesticide (not likely to cause infection) for healthy individuals but recommends precautions for immunocompromised individuals; EFSA has similarly concluded that occupational risk to healthy workers is low. The precautionary approach would suggest that individuals who are immunocompromised should avoid high-exposure agricultural activities involving P. lilacinum biopesticide application.

What treatment works for Purpureocillium lilacinum infection?

Treatment of P. lilacinum infections is challenging due to its intrinsic resistance to several first-line antifungal agents, requiring careful agent selection based on susceptibility testing and clinical presentation. In vitro susceptibility profile (what the laboratory data shows): amphotericin B—frequently shows high MICs (minimum inhibitory concentrations) or intrinsic resistance; amphotericin B, the traditional broad-spectrum antifungal ‘last resort,’ is not reliably effective against P. lilacinum. Fluconazole—not active; P. lilacinum is intrinsically resistant to fluconazole. Itraconazole—variable activity; some clinical isolates show acceptable MICs; has been used clinically with variable success. Voriconazole—consistently shows the lowest MICs in susceptibility testing and is the most widely recommended treatment based on accumulated clinical case reports and series; considered the preferred agent for most P. lilacinum infections. Posaconazole—also shows reasonable activity in vitro; used as alternative or for infections not responding to voriconazole. Echinocandins (caspofungin, micafungin, anidulafungin)—in vitro activity exists but clinical experience is limited; not typically used as monotherapy. Clinical approach combining antifungals with surgery: for localised infections (skin, eye, subcutaneous tissue), surgical debridement significantly improves outcomes by reducing fungal burden; for keratitis, topical voriconazole eye drops (often compounded as they are not commercially available) combined with systemic antifungal therapy; removal of infected catheters or devices is essential for device-associated infections. Duration: often months of therapy for invasive infections; shorter courses may be sufficient for superficial presentations.